PURPOSE: We sought the association of preoperative serum total testosterone (tT), hypogonadism, 17β estradiol (E2), and sex hormone-binding globulin (SHBG) with early biochemical recurrence (BCR) after radical prostatectomy (RP). METHODS: Sex steroids were assessed the day before surgery (7-11 a.m.) in a cohort of 605 patients with a median follow-up of 24 months following RP. Cox regression models tested the association between predictors [including age, body mass index (BMI), prostate-specific antigen (PSA), clinical stage, biopsy Gleason scores, tT, hypogonadism, E2, and SHBG] and early BCR (defined as a PSA ≥ 0.1 ng/ml that occurred within 24 months after RP). RESULTS: Early BCR was found in 34 (5.6 %) patients. Patients with BCR did not differ in terms of age, BMI, serum PSA, tT, E2, and SHBG levels, rate of hypogonadism, and clinical stage as compared with those without BCR (all p ≥ 0.05). Conversely, patients with BCR showed a greater prevalence of biopsy Gleason scores ≥4 + 3 (all p ≤ 0.001). At multivariable Cox regression analysis, tT [hazard ratio (HR): 1.43; p = 0.03] E2 (HR: 1.05; p = 0.04), SHBG (HR: 1.29; p = 0.02), and biopsy Gleason scores equal to 4 + 3 (HR: 3.37; p = 0.04) and ≥8 (HR: 20.06; p < 0.001) achieved independent predictor status for early BCR. Conversely, no significant associations were found for all the other predictors. CONCLUSIONS: Current findings show that preoperative serum sex steroids are independent predictors of early BCR in a homogeneous, large cohort of nonscreened patients treated with RP.
PURPOSE: We sought the association of preoperative serum total testosterone (tT), hypogonadism, 17β estradiol (E2), and sex hormone-binding globulin (SHBG) with early biochemical recurrence (BCR) after radical prostatectomy (RP). METHODS: Sex steroids were assessed the day before surgery (7-11 a.m.) in a cohort of 605 patients with a median follow-up of 24 months following RP. Cox regression models tested the association between predictors [including age, body mass index (BMI), prostate-specific antigen (PSA), clinical stage, biopsy Gleason scores, tT, hypogonadism, E2, and SHBG] and early BCR (defined as a PSA ≥ 0.1 ng/ml that occurred within 24 months after RP). RESULTS: Early BCR was found in 34 (5.6 %) patients. Patients with BCR did not differ in terms of age, BMI, serum PSA, tT, E2, and SHBG levels, rate of hypogonadism, and clinical stage as compared with those without BCR (all p ≥ 0.05). Conversely, patients with BCR showed a greater prevalence of biopsy Gleason scores ≥4 + 3 (all p ≤ 0.001). At multivariable Cox regression analysis, tT [hazard ratio (HR): 1.43; p = 0.03] E2 (HR: 1.05; p = 0.04), SHBG (HR: 1.29; p = 0.02), and biopsy Gleason scores equal to 4 + 3 (HR: 3.37; p = 0.04) and ≥8 (HR: 20.06; p < 0.001) achieved independent predictor status for early BCR. Conversely, no significant associations were found for all the other predictors. CONCLUSIONS: Current findings show that preoperative serum sex steroids are independent predictors of early BCR in a homogeneous, large cohort of nonscreened patients treated with RP.
Authors: Abdelouahid Tajar; Gianni Forti; Terence W O'Neill; David M Lee; Alan J Silman; Joseph D Finn; György Bartfai; Steven Boonen; Felipe F Casanueva; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Ilpo T Huhtaniemi; Frederick C W Wu Journal: J Clin Endocrinol Metab Date: 2010-02-19 Impact factor: 5.958
Authors: Stefan Aufderklamm; Jörg Hennenlotter; Tilman Todenhoefer; Georgios Gakis; David Schilling; Ulrich Vogel; Ursula Kuehs; Johannes Dlugosch; Judith Knapp; Axel Merseburger; Valentina Gerber; Anna Ordelheide; Joachim Hevler; Arnulf Stenzl; Christian Schwentner Journal: World J Urol Date: 2011-10-04 Impact factor: 4.226
Authors: Martin Andreas Røder; Ib Jarle Christensen; Kasper D Berg; Lisa Gruschy; Klaus Brasso; Peter Iversen Journal: BJU Int Date: 2011-08-18 Impact factor: 5.588
Authors: Hendrik Isbarn; Manuela Wanner; Georg Salomon; Thomas Steuber; Thorsten Schlomm; Jens Köllermann; Guido Sauter; Alexander Haese; Hans Heinzer; Hartwig Huland; Markus Graefen Journal: BJU Int Date: 2009-12-11 Impact factor: 5.588
Authors: Jochen Walz; Felix K-H Chun; Eric A Klein; Alwyn Reuther; Fred Saad; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz Journal: J Urol Date: 2008-12-13 Impact factor: 7.450
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani Journal: Curr Urol Date: 2017-05-30